Campus: UMD | Building: School of Public Health | Room: 2387 Phone: (301) 405-2029 | Email:firstname.lastname@example.org
By appointment only.
Dr Glover is a Professor in the Department of Behavioral & Community Health, & Founding Director of the Center for Health Behavior Research at the Maryland School of Public Health, University of Maryland, College Park, MD. Dr Glover has more than 200 publications and approximately $33 million dollars in grant funding to his credit. He maintains a keen interest in the physician's role in smoking cessation & has delivered over 550 invited medical grand rounds/workshops on the subject to physicians throughout the world. Moreover, he has delivered over 335 national & international professional presentations to various medical & health professional organizations.
Structured Clinical Interview for Axis I DSM-IV Disorder (SCID)
Mini International Neuropsychiatric Interview (MINI)
Hamilton Rating Scale for Depression (HAM-D)
Hamilton Anxiety Scale (HAM-A)
Montgomery Asberg Depression Rating Scale (MADRS)
NIH’s Human Participants Protection Education for Research Teams Training
Association of Clinical Research Professionals, Good Clinical Practices for Clinical Investigators
HLTH 688W Professional Writing
Honors and Awards
Named the 2003 Distinguished Scholar for AAHE, the 2005 Alliance Scholar for AAHPERD, selected by the University of Maryland as a “Rainmaker” which designates a Research Leader, and in 2008 received the coveted American Academy of Health Behavior Research Laureate Medallion for his contribution to health behavior research. As the founder of the American Academy of Health Behavior he was also awarded the Lifetime Achievement Award by the Academy.
DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM. A comparison of sustained-release bupropion & placebo for smoking cessation. New England Journal of Medicine, 337:1195-1202.
Daughton D, Fortmann S, Glover ED, Hatsukami D, Heatley S, Lichtenstein E, Repsher L, MillatmalT, Killen J, Nowak R, Ullrich F, Rennard S. The smoking cessation efficacy of varying doses of nicotine patch delivery systems four years to five years post quit day. Preventive Medicine, 28:113-119.
Hayford KE, Patten CA, Rummans TA, Schroeder DR, Offord KP, Croghan IT, Glover ED, Sachs DPL, Hurt RD. Effectiveness of bupropion for smoking cessation in subjects with a history of majordepression or alcoholism. British Journal of Psychiatry, 174:173-178.
Johnston JA, Fiedler-Kelly J, Glover ED, Sachs DPL, Grasela T, DeVeaugh-Geiss J. Relationship between drug exposure and the efficacy and safety of bupropion sustained release for smoking cessation. Nicotine & Tobacco Research, 3(2):131-140.
Glover ED, Glover PN, Sullivan CR, Cerullo C, Hobbs GR. A comparison of sustained-release bupropion & placebo for smokeless tobacco cessation. American Journal of Health Behavior, 26;(5):386-393.
Glover ED, Glover PN, Franzon M, Sullivan CR, Cerullo CL, Howell RM, Keyes GG, Nilsson F, Hobbs GR. A comparison of a nicotine sublingual tablet & placebo for smoking cessation. Nicotine & Tobacco Research, 4:441-450.
Rennard SI, Glover ED, Leischow S, Daughton D, Glover PN, Muramoto M, Franzon F, Danielsson T, Landfeldt B, Westin A. Efficacy of nicotine inhaler in smoking reduction: a double-blind, randomized trial. Nicotine & Tobacco Research, 8(4):555-564.
Glover ED, Glover PN, Laflin M, Nochur SV, Strnad JV. Sensitivity and specificity of a reagent-impregnated test strip in identifying smokeless tobacco users. Nicotine & Tobacco Research, 9(4):499-503.
Glover ED, Laflin MT, Schuh KJ, Schuh L, Nides M, Christen AG, Glover PN, Strnad JV. A randomized, controlled trial to assess the efficacy and safety of a transdermal delivery system of nicotine/mecamylamine in cigarette smokers. Addiction, 102:795-802.
Glover ED, Rath J, Sharma E, Glover PN, Laflin MT, Tønnesen P, Repsher L, Quiring J. A multi-center, phase-3 trial of lobeline sulfate for smoking cessation. American Journal of Health Behavior, 34(1):101-109.
Hatsukami DK, Jorenby DE, Gonzales D, Rigotti N, Glover ED, Oncken C, Tashkin D, Reus V, Akhavain R, Fahim REF, Kessler PD, Niknian M, Kalnik MW, Rennard SI. Immunogenicity and smoking cessation outcomes for a novel nicotine immunotherapeutic: anti-nicotine elicited antibodies enhance quitting and support long-term abstinence. Clinical Pharmacology Therapeutics, DOI 1038/clpt.2010.317.
Kahn R, Gorgon L, Jones K, McSherry F, Glover ED, Anthenelli RM, Jackson T, Williams J, Murtaugh C, Montoya I, Yu E, Elkashef A. Selegiline transdermal system (STS) as an aid for smoking cessation. Nicotine & Tobacco Research, 14(3):March 2012;377-382. DOI:10.1093/ntr/ntr143.
Ebbert JO, Severson HH, Danaher BG, Schroeder DR, Glover ED. A comparison of three smokeless tobacco dependence measures. Addictive Behaviors, 37(2012):1271-1277.